Globus Medical, Inc. (GMED)
| Market Cap | 8.18B |
| Revenue (ttm) | 927.90M |
| Net Income (ttm) | 184.05M |
| Shares Out | 100.45M |
| EPS (ttm) | 1.80 |
| PE Ratio | 45.15 |
| Forward PE | 35.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 542,019 |
| Open | 80.52 |
| Previous Close | 80.95 |
| Day's Range | 80.40 - 81.46 |
| 52-Week Range | 48.00 - 84.23 |
| Beta | 1.08 |
| Analysts | Buy |
| Price Target | 85.92 (+5.8%) |
| Est. Earnings Date | Oct 27, 2021 |
About GMED
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders. Its offers spine products, such as consists of traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies, such as dynamic stabilization, total disc replacement, and interspinous distraction devices; interventio...
Financial Performance
In 2020, Globus Medical's revenue was $789.04 million, an increase of 0.47% compared to the previous year's $785.37 million. Earnings were $102.29 million, a decrease of -34.10%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for Globus Medical stock is "Buy." The 12-month stock price forecast is 85.92, which is an increase of 5.79% from the latest price.
News
Here's Why You Should Retain Globus Medical (GMED) for Now
Investors are optimistic about Globus Medical (GMED) owing to domestic growth in the spine business and robust demand for the HEDRON line of products.
Globus Medical (GMED) Up 4.9% Since Last Earnings Report: Can It Continue?
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock?
Globus Medical (GMED) Gets FDA Nod for Excelsius3D
The receipt of FDA's 510(k) clearance for Globus Medical's (GMED) Excelsius3D is expected to expand the company's presence in the intraoperative imaging system space.
FDA Approves Globus Medical's Consolidated Imaging System
The FDA has approved Globus Medical Inc's (NYSE:GMED) Excelsius3D, an intelligent intraoperative 3-in-1 imaging system. The imaging platform consolidates 360o cone-beam CT, fluoroscopy, and high-resolut...
Globus Medical Announces FDA 510(k) Clearance for Excelsius3D™
Excelsius3D™ – Intelligent 3-in-1 Intraoperative Imaging System Excelsius3D™ – Intelligent 3-in-1 Intraoperative Imaging System
Globus Medical (GMED) Q2 Earnings Beat Estimates, 2021 View Up
Pull-through from robotics, contributions from new product introductions and resurgence in the Globus Medical's (GMED) biologics business drove second-quarter growth.
Globus Medical (GMED) Beats Q2 Earnings and Revenue Estimates
Globus Medical (GMED) delivered earnings and revenue surprises of 24.44% and 10.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical Reports Second Quarter 2021 Results
AUDUBON, Pa., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2021.
Why Globus Medical (GMED) Could Beat Earnings Estimates Again
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is Globus Medical's Robotic Surgery Business a Winner?
It's still early, but things look promising.
Globus Medical (GMED) Earnings Expected to Grow: Should You Buy?
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is Why Growth Investors Should Buy Globus Medical (GMED) Now
Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Globus Medical (GMED) Hits 52-Week High, Can the Run Continue?
Globus Medical (GMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Invest In Globus Medical (GMED) Now
Strong first-quarter performance by the U.S. Spine and Enabling Technologies business contributed to Globus Medical's (GMED) top line.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Globus Medical (GMED) Marks New Milestone for ExcelsiusGPS
Globus Medical's (GMED) ExcelsiusGPS Robotic Navigation system reaches new surgical milestone for spinal procedures.
Globus Medical Schedules Second Quarter Earnings Release and Conference Call
AUDUBON, Pa., July 16, 2021 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the second quarter ended June 30, 2...
Globus Medical Announces Completion of 20,000 Procedures Utilizing ExcelsiusGPS®
Robotic Navigation System helps surgeons increase accuracy, reduce radiation, and save time in OR Robotic Navigation System helps surgeons increase accuracy, reduce radiation, and save time in OR
3 Unstoppable Stocks to Buy and Hold for Years
They are in industries where the annual growth rate is 10% or better.
Globus Medical (GMED) Hits New 52-Week High: What's Driving It?
Investors are optimistic about Globus Medical (GMED) owing to significant trend improvement and the company's focus on product development.
Why Is Globus Medical (GMED) Down 3.8% Since Last Earnings Report?
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock?
Globus Medical (GMED) Moves 5.4% Higher: Will This Strength Last?
Globus Medical (GMED) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Globus Medical (GMED) Q1 Earnings Beat Estimates, Margins Up
Globus Medical's (GMED) first-quarter 2021 revenues improved year over year on strength in Enabling Technologies and U.S. Spine.